Our Vision: Creating Future Cell Therapy Miracles Together
Minaris Regenerative Medicine is a leading global contract development and manufacturing organization (CDMO) dedicated to the production of cell and gene therapy products. For more than 20 years, we have been offering clinical and commercial manufacturing services, development solutions, and technologies while providing outstanding quality and reliability.
Our Vision: Creating Future Cell Therapy Miracles Together
Our state-of-the-art facilities located within the United States (New Jersey and California), Europe (Germany), and Asia (Japan) allow us to supply patients worldwide with life-changing therapies.
As a pioneer within this industry, we are proud to have built strong relationships with a number of international clients, ranging from big pharma to biotech to academia.
Our client-focused approach is designed to deliver world-class service to your specific needs and unique challenges. Our goal is to be viewed as your partner and an extension of your in-house team by delivering the expertise, strategy, teamwork, efficiency, and accessibility you demand. Doing so allows these life-changing therapeutics to be available to patients worldwide at an accelerated rate.
Our Mission: We commit our experience to our clients, by providing global manufacturing services, development solutions, and technologies for cell and gene therapies to improve society’s well-being.
Minaris is derived from the Japanese word "mirai", meaning future, and the English word "miracle." Our new name stands for our commitment to constantly push the boundaries of medicine and provide future miracles to the patients we serve.
Minaris Regenerative Medicine, LLC based in Allendale, NJ and Mountain View, CA, formerly named Hitachi Chemical Advanced Therapeutics Solutions (HCATS) and founded as Progenitor Cell Therapy (PCT) in 1999.
Minaris Regenerative Medicine GmbH based in Munich, Germany, formerly named apceth Biopharma GmbH and founded in 2007.
Minaris Regenerative Medicine Co., Ltd. based in Yokohama, formerly named Showa Denko Materials Co., Ltd., and founded as Hitachi Chemical Co., Ltd. in 2018.
Our global leadership team has together more than 100 years’ experience of cell and gene therapy and the healthcare sector.
Kazuchika Furuishi, PhD, is Corporate Officer and General Manager, Regenerative Medicine Business Sector of Showa Denko Materials Co., Ltd. and CEO of Minaris Regenerative Medicine, LLC since April 2020. Dr. Furuishi has almost 10 years of experience in research and education (Biochemistry, virology and oncology) at the Faculty of Pharmaceutical Science as Assistant Professor at Kumamoto University. He has over 17 years of working experience with major global life science companies and senior leadership roles in global organizations. He also has almost six years of experience working for serving Pharma research and development and manufacturing under control of GMP/GLP and business development activities of genotyping testing to prepare for IVD applications. In 2015, Dr. Furuishi started a private consulting firm to support establishing legal entities in Japan, business development for CRO and CMO businesses and in a liaison in the life science market for a US consulting firm. Since 2012, he has been involved in the industrialization of regenerative medicine through a variety of activities, including through his prior role at Hitachi Chemical Co. Ltd., as Deputy General Manager of its Regenerative Medicine Business Sector, which he has held since 2017. Furuishi received his Ph.D. in Pharmaceutical Science in 1999 from Kumamoto University.
Hiroto Bando, PhD, is Deputy General Manager, Regenerative Medicine Business Sector of Showa Denko Materials Co., Ltd. He is responsible for coordinating global Business Development activities and develop business strategies that provides global leaderships and oversight for Minaris Regenerative Medicine.
Hiroto brings to Minaris Regenerative Medicine over twenty years’ experience in the pharmaceutical industry. Most recently, he worked at Fujifilm for the last two years as Senior Manager, Pharmaceutical Products Division. His work has led to a major contract for Fujifilm to manufacture a COVID-19 vaccine for VLP Therapeutic. Hiroto has also spent almost 22 years of his career at Takeda Pharmaceutical Company in roles of increasing responsibility, including Senior Director and Global Head of Cell Manufacturing Strategy for the company’s regenerative medicine unit from 2016-2018.
Hiroto received his PhD in pharmaceutical science from Kyoto University and performed post-doctoral work at the College of Pharmacy at the University of Texas. He also holds an MBA from Kenichi Ohmae Graduate School of Business.
Dusan is Global Chief Financial Officer, Regenerative Medicine Business Sector of Showa Denko Materials Co., Ltd and CEO of Minaris Regenerative Medicine GmbH. Before, he was Managing Director of Minaris Regenerative Medicine GmbH (formerly named apceth Biopharma GmbH) since 2020 and has served as CFO since 2016. Previously, he was CFO for Accovion GmbH, a Contract Research Organization (CRO) headquartered close to Frankfurt, Germany. Dusan is a Certified Management Accountant by training and has gained more than 15 years’ experience in the healthcare sector.
Jo Anne Valentino is Global Head of Quality, Regenerative Medicine Business Sector of Showa Denko Materials Co., Ltd. and Vice President of Minaris Regenerative Medicine, LLC. Jo Anne is an accomplished Quality Assurance senior leader with demonstrated success in challenging compliance environments including transitions resulting from mergers and acquisitions.
Jo Anne joined the company (then called Hitachi Chemical Advanced Therapeutics Solutions) in January 2019 as Global Quality Head. In her position as Global Head of Quality, she is responsible to develop and lead the implementation of the company’s integrated global quality strategy in alignment with the overall global business strategy and Health Authority regulations. She is accountable for ensuring that the company’s quality strategy is translated into global and local executable policies, processes, training programs, and organizational structures, as well as implementing governance processes to monitor the effectiveness of the implementation of the quality systems.
For more than seven years, Jo Anne worked at Novartis in quality positions of increasing responsibility. Most recently, she was Executive Director, Quality Head, External Supply Operations, Americas region. Prior to Novartis, Jo Anne was in leadership positions at Merck and Schering-Plough in operations and quality, as well as product and process development at Reckitt Benckiser. She received her MS in management from Stevens Institute of Technology and her BS in chemical engineering from Manhattan College.